In addition, the activation of GLP-1R is to be explored in other diseases such as Alzheimer’s disease, Parkinson’s disease, non-alcoholic fatty liver disease and non-alcoholic steatohepatitis in addition to traditional diabetes treatment. This evidence concerns the gene GLP1R and metabolic dysfunction-associated steatotic liver disease.